 Heather Moore
Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 8 | 2024 | 2059 | 1.020 |
Why?
| | Oxazepines | 2 | 2019 | 4 | 0.860 |
Why?
| | Imidazoles | 2 | 2019 | 239 | 0.770 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2014 | 62 | 0.510 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 292 | 0.400 |
Why?
| | Biomarkers | 2 | 2019 | 3736 | 0.340 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2009 | 0.330 |
Why?
| | Carbolines | 2 | 2024 | 29 | 0.280 |
Why?
| | Patient Discharge | 3 | 2022 | 857 | 0.240 |
Why?
| | Receptors, Estrogen | 5 | 2024 | 392 | 0.220 |
Why?
| | Respiration, Artificial | 2 | 2017 | 595 | 0.210 |
Why?
| | Pyridines | 2 | 2024 | 445 | 0.210 |
Why?
| | Piperazines | 1 | 2024 | 331 | 0.190 |
Why?
| | Estrogen Receptor alpha | 1 | 2022 | 128 | 0.190 |
Why?
| | Cell Line, Tumor | 3 | 2019 | 2913 | 0.190 |
Why?
| | Paclitaxel | 1 | 2019 | 200 | 0.150 |
Why?
| | Continuity of Patient Care | 2 | 2017 | 281 | 0.150 |
Why?
| | Chemokines, CXC | 1 | 2017 | 64 | 0.140 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2014 | 38 | 0.140 |
Why?
| | Simulation Training | 1 | 2017 | 72 | 0.130 |
Why?
| | Ventilator Weaning | 1 | 2016 | 34 | 0.130 |
Why?
| | Hedgehog Proteins | 1 | 2017 | 176 | 0.130 |
Why?
| | Receptor, ErbB-2 | 3 | 2024 | 327 | 0.130 |
Why?
| | Surgery, Computer-Assisted | 1 | 2016 | 70 | 0.120 |
Why?
| | Airway Management | 1 | 2016 | 76 | 0.120 |
Why?
| | Laryngoscopy | 1 | 2016 | 99 | 0.120 |
Why?
| | Tracheostomy | 1 | 2016 | 104 | 0.120 |
Why?
| | Female | 13 | 2024 | 64890 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2244 | 0.110 |
Why?
| | Preoperative Care | 1 | 2016 | 343 | 0.110 |
Why?
| | Receptor, Notch1 | 1 | 2014 | 66 | 0.110 |
Why?
| | Quality Improvement | 2 | 2017 | 1020 | 0.100 |
Why?
| | Signal Transduction | 3 | 2017 | 4809 | 0.100 |
Why?
| | Mice, SCID | 1 | 2013 | 337 | 0.100 |
Why?
| | Carcinoma | 1 | 2014 | 211 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 317 | 0.100 |
Why?
| | Ultrasonography | 1 | 2016 | 757 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 167 | 0.100 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 178 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 546 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 985 | 0.090 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2017 | 467 | 0.090 |
Why?
| | Length of Stay | 1 | 2016 | 1077 | 0.090 |
Why?
| | Postmenopause | 2 | 2023 | 310 | 0.090 |
Why?
| | Caregivers | 1 | 2017 | 769 | 0.090 |
Why?
| | Humans | 15 | 2024 | 125132 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1442 | 0.090 |
Why?
| | Asthma | 1 | 2022 | 2150 | 0.080 |
Why?
| | Cell Movement | 1 | 2013 | 913 | 0.080 |
Why?
| | Phosphorylation | 1 | 2013 | 1694 | 0.080 |
Why?
| | Mice | 3 | 2022 | 15984 | 0.060 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2023 | 2 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2023 | 115 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2022 | 39 | 0.050 |
Why?
| | Animals | 5 | 2022 | 34345 | 0.050 |
Why?
| | Aromatase Inhibitors | 1 | 2022 | 52 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 195 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 301 | 0.050 |
Why?
| | Tamoxifen | 1 | 2022 | 199 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 338 | 0.050 |
Why?
| | Human Genome Project | 1 | 2001 | 16 | 0.050 |
Why?
| | Progesterone | 1 | 2022 | 243 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 574 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2022 | 327 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 3520 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 208 | 0.040 |
Why?
| | Estrogens | 1 | 2022 | 337 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 186 | 0.040 |
Why?
| | Genome, Human | 1 | 2001 | 396 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2001 | 767 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 573 | 0.040 |
Why?
| | Long-Term Care | 1 | 2017 | 78 | 0.040 |
Why?
| | Transitional Care | 1 | 2017 | 39 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2022 | 734 | 0.040 |
Why?
| | Anilides | 1 | 2017 | 70 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1341 | 0.030 |
Why?
| | Middle Aged | 3 | 2023 | 29112 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2014 | 132 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 9790 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2014 | 138 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 895 | 0.030 |
Why?
| | Infant | 2 | 2017 | 8625 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 334 | 0.030 |
Why?
| | Child, Preschool | 2 | 2017 | 9938 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1431 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 745 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1885 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1233 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1970 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1108 | 0.020 |
Why?
| | Aged | 2 | 2019 | 20859 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1743 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1195 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4159 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4824 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3047 | 0.020 |
Why?
| | Male | 4 | 2017 | 60793 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3274 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6936 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2492 | 0.020 |
Why?
| | Child | 2 | 2017 | 20014 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5102 | 0.020 |
Why?
| | Adult | 2 | 2019 | 33168 | 0.020 |
Why?
| | Lung | 1 | 2017 | 3865 | 0.010 |
Why?
| | Neoplasms | 1 | 2017 | 2340 | 0.010 |
Why?
| | Chromosome Banding | 1 | 2001 | 21 | 0.010 |
Why?
| | Physical Chromosome Mapping | 1 | 2001 | 17 | 0.010 |
Why?
| | Pseudogenes | 1 | 2001 | 20 | 0.010 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2001 | 20 | 0.010 |
Why?
| | Consensus Sequence | 1 | 2001 | 71 | 0.010 |
Why?
| | DNA, Intergenic | 1 | 2001 | 25 | 0.010 |
Why?
| | Retroelements | 1 | 2001 | 35 | 0.010 |
Why?
| | Gene Duplication | 1 | 2001 | 65 | 0.010 |
Why?
| | United States | 1 | 2017 | 13613 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2001 | 106 | 0.010 |
Why?
| | CpG Islands | 1 | 2001 | 125 | 0.010 |
Why?
| | Genes | 1 | 2001 | 237 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 11385 | 0.010 |
Why?
| | Introns | 1 | 2001 | 241 | 0.010 |
Why?
| | Exons | 1 | 2001 | 316 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2001 | 527 | 0.010 |
Why?
| | Species Specificity | 1 | 2001 | 592 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 19411 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2001 | 458 | 0.010 |
Why?
| | Computational Biology | 1 | 2001 | 616 | 0.010 |
Why?
| | Databases, Factual | 1 | 2001 | 1298 | 0.010 |
Why?
| | Genetic Variation | 1 | 2001 | 970 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 951 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1618 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2001 | 2135 | 0.010 |
Why?
| | Phenotype | 1 | 2001 | 3153 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|